cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A) (PDE4A)

cAMP-specific 3',5'-cyclic phosphodiesterase 4A (PDE4A) is a member of the phosphodiesterase 4 family, which plays a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP) by catalyzing its hydrolysis [ResearchGate, UniProt]. PDE4A is widely expressed in immune cells, the central nervous system, and cardiovascular tissues, where it acts as a key modulator of signal transduction pathways involved in inflammation and neurotransmission [ResearchGate, Wikipedia]. In inflammatory conditions such as chronic obstructive pulmonary disease (COPD), asthma, and psoriasis, PDE4A-mediated cAMP degradation contributes to the production of pro-inflammatory cytokines [Patsnap, NIH]. Consequently, PDE4A is a major therapeutic target for PDE4 inhibitors like roflumilast and apremilast, which increase cAMP levels to exert anti-inflammatory and immunomodulatory effects [Frontiers, Patsnap]. Beyond inflammation, PDE4A is also investigated for its roles in cognitive function and mood regulation, making it a potential target for neuropsychiatric and neurodegenerative disorders [ResearchGate, NIH].

Other names

DPDE2PDE4PDE46cAMP-specific phosphodiesterase 4A

PDE4A inhibitors work by binding to the catalytic site of the enzyme, preventing the hydrolysis of the second messenger cyclic adenosine monophosphate (cAMP) [Patsnap, NIH]. This leads to an accumulation of intracellular cAMP, which activates protein kinase A (PKA) and other downstream effectors [Patsnap, NIH]. The activation of these pathways results in the suppression of pro-inflammatory transcription factors like NF-kappaB and the reduction of inflammatory cytokines such as TNF-alpha, IL-17, and IL-23, while promoting the expression of anti-inflammatory mediators like IL-10 [Patsnap, NIH, Frontiers].